

Author Index Volume 19 (2017)

The issue number is given in front of the pagination

- Abudureyimu, K., see Maimaiti, Y. (4) 411–418
Ahmad, A., M. Raish, M. Shahid, S. Batra, V. Batra and S.A. Husain, The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer (4) 375–381
Ahn, H.-S., see Choi, B. (3) 231–239
Aili, A., see Maimaiti, Y. (4) 411–418
Al Ahmed, H.A. and O. Nada, E2F3 transcription factor: A promising biomarker in lung cancer (1) 21–26
Anderson, K.S., see Hanna, G.J. (2) 129–136
Azami, S., see Rismani, E. (2) 151–159

Bajic, V., see Petrovic, N. (2) 119–128
Bao, X., see Yang, B. (1) 65–73
Batra, S., see Ahmad, A. (4) 375–381
Batra, V., see Ahmad, A. (4) 375–381
Bellampalli, R., M. Vohra, K. Sharma, N. Bhaskaranand, K.G. Bhat, K. Prasad, A.R. Sharma, K. Satyamoorthy and P.S. Rai, Acute lymphoblastic leukemia and genetic variations in *BHMT* gene: Case-Control study and computational characterization (4) 393–401
Bhaskaranand, N., see Bellampalli, R. (4) 393–401
Bhat, K.G., see Bellampalli, R. (4) 393–401

Cai, K., see Yang, B. (1) 65–73
Cai, Z., J. Xiao, X. He, J. Ke, Y. Zou, Y. Chen, X. Wu, X. Li, L. Wang, J. Wang, P. Lan and X. Wu, Accessing new prognostic significance of preoperative carcinoembryonic antigen in colorectal cancer receiving tumor resection: more than positive and negative (2) 161–168
Canto, P., J.B. Granados, G. Ferial-Bernal, R.M. Coral-Vázquez, E. García-García, M.E. Tejeda, A. Tapia, D. Rojano-Mejía and J.P. Méndez, *PPARGCIA* and *ADIPOQ* polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity (3) 297–303

Cao, Y., see Zhang, Z.J. (2) 169–175
Cao, Z., see Deng, J. (1) 57–64
Chau, N.G., see Hanna, G.J. (2) 129–136
Chen, E., F. Zheng, X. Yuan, Y. Ye, X. Li, Y. Dai and L. Chen, The effect of *TMEFF2* methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma (2) 207–212
Chen, H., see Cheng, J. (1) 85–92
Chen, H., see Ning, L. (1) 75–83
Chen, J.-X., see Zhang, J. (3) 257–262
Chen, L., see Chen, E. (2) 207–212
Chen, W., see Deng, J. (1) 57–64
Chen, X., see Hong, T. (1) 103–111
Chen, X., see Shen, H. (4) 365–373
Chen, X., see Yang, D. (4) 425–436
Chen, X., X. Lai, C. Wu, Q. Tian, T. Lei, J. Pan and G. Huang, Decreased SIRT4 protein levels in endometrioid adenocarcinoma tissues are associated with advanced AJCC stage (4) 419–424
Chen, Y., see Cai, Z. (2) 161–168
Cheng, D.-Q., see Xu, Y.-J. (1) 113–117
Cheng, G., see Su, Y. (3) 289–296
Cheng, J., S. Fu, C. Wei, M. Tania, Md.A. Khan, S. Imani, B. Zhou, H. Chen, X. Xiao, J. Wu and J. Fu, Evaluation of *PIK3CA* mutations as a biomarker in Chinese breast carcinomas from Western China (1) 85–92
Cheng, Y., see Yang, N. (3) 263–269
Cheng, Z.-M., see Hou, S.-Z. (3) 249–256
Choe, H.-N., see Choi, B. (3) 231–239
Choi, B., H.-J. Lee, J. Min, H.-N. Choe, Y.-S. Choi, Y.-G. Son, H.-S. Ahn, Y.-S. Suh, J.R. Goldenring and H.-K. Yang, Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer (3) 231–239
Choi, Y.-S., see Choi, B. (3) 231–239
Chu, J., see Yang, B. (1) 65–73
Coral-Vázquez, R.M., see Canto, P. (3) 297–303
Cui, Z., see Zhao, Q. (4) 455–463

- Dai, L., see Yang, Z. (3) 313–325
 Dai, Y., see Chen, E. (2) 207–212
 Davidovic, R., see Petrovic, N. (2) 119–128
 Deng, J., W. Chen, Y. Du, W. Wang, G. Zhang, Y. Tang, Z. Qian, P. Xu, Z. Cao and Y. Zhou, Synergistic efficacy of Cullin1 and MMP-2 expressions in diagnosis and prognosis of colorectal cancer (1) 57–64
 Ding, J., J.E. Karp and A. Emadi, Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments (4) 353–363
 Dong, L., see Maimaiti, Y. (4) 411–418
 Dong, L., see Xue, L. (2) 193–197
 Dong, L.-N., see Yang, N. (3) 263–269
 Dou, C., X. Jin, L. Sun, B. Zhang, M. Han and T. Li, FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition (4) 447–454
 Du, Y., see Deng, J. (1) 57–64
 Du, Z., S. Niu, X. Xu and Q. Xu, MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance (2) 221–230
- El-Anwar, M.W., see Hussein, S. (3) 279–287
 Emadi, A., see Ding, J. (4) 353–363
 Estiar, M.A., F. Javan, A. Zekri, M. Mehrazin and P. Mehdipour, Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma (3) 341–351
- Fan, T., see Yan, H. (2) 185–192
 Fazeli, M.S., see Rismani, E. (2) 151–159
 Fedarko, N.S., see Thein, M.S. (4) 383–391
 Fei, Z., see Zhang, M. (4) 437–445
 Feria-Bernal, G., see Canto, P. (3) 297–303
 Fu, J., see Cheng, J. (1) 85–92
 Fu, S., see Cheng, J. (1) 85–92
- Gao, M., see Zhang, M. (4) 437–445
 Gao, P., S. Wang, F. Jing, J. Zhan and Y. Wang, microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/E-cadherin signaling (1) 11–20
 Gao, Q., see Li, L. (4) 403–409
 Gao, W., see Rong, B. (1) 35–43
 García-García, E., see Canto, P. (3) 297–303
 Goldenring, J.R., see Choi, B. (3) 231–239
- Granados, J.B., see Canto, P. (3) 297–303
 Guo, H., see Zhang, S. (1) 27–34
 Guo, L., see Zhang, Z.J. (2) 169–175
 Guo, Q., see Yang, B. (1) 65–73
- Haddad, R.I., see Hanna, G.J. (2) 129–136
 Han, M., see Dou, C. (4) 447–454
 Hanna, G.J., V. Sridharan, D.N. Margalit, S.K. La Follette, N.G. Chau, G. Rabinowits, J.H. Lorch, R.I. Haddad, R.B. Tishler, K.S. Anderson and J.D. Schoenfeld, Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma (2) 129–136
 Hashemian, M., see Motalebzadeh, J. (1) 51–55
 He, H., see Xue, L. (2) 193–197
 He, J., see Xu, Y.-J. (1) 113–117
 He, X., see Cai, Z. (2) 161–168
 He, X., see Liu, C. (3) 335–340
 Hong, Q., see Zhang, S. (1) 27–34
 Hong, T., D. Shen, X. Chen, X. Wu and D. Hua, Preoperative plasma fibrinogen, but not D-dimer might represent a prognostic factor in non-metastatic colorectal cancer: A prospective cohort study (1) 103–111
 Hosseinpour, Y., see Motalebzadeh, J. (1) 51–55
 Hou, S.-Z., Z.-M. Cheng, Y.-B. Wu, Y. Sun, B. Liu, M.-X. Yuan and X.-D. Wang, Evaluation of short-term and long-term efficacy of surgical and non-surgical treatment in patients with early-stage small cell lung cancer: A comparative study (3) 249–256
 Hou, Z., see Huang, Q. (2) 137–144
 Hu, G., see Liu, C. (3) 335–340
 Hu, W., see Yang, Z. (3) 313–325
 Hua, D., see Hong, T. (1) 103–111
 Huang, G., see Chen, X. (4) 419–424
 Huang, J., see Li, L. (3) 305–311
 Huang, Q., C. Wang, Z. Hou, G. Wang, J. Lv, H. Wang, J. Yang, Z. Zhang and H. Zhang, Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas (2) 137–144
 Huang, T., see Maimaiti, Y. (4) 411–418
 Huang, W., see Zhang, Y. (2) 145–150
 Husain, S.A., see Ahmad, A. (4) 375–381
 Hussein, S., H. Mosaad, H.E. Rashed and M.W. El-Anwar, Up-regulated miR-221 expression as a molecular diagnostic marker in laryngeal squamous cell carcinoma and its correlation with Apaf-1 expression (3) 279–287

- Imani, S., see Cheng, J. (1) 85–92
 Ingaramo, M.C., see Thein, M.S. (4) 383–391
 Isenovic, R.E., see Petrovic, N. (2) 119–128
- Jain, A., see Thein, M.S. (4) 383–391
 Javan, F., see Estiar, M.A. (3) 341–351
 Ji, E., see Su, Y. (3) 289–296
 Ji, Z.-G., see Wang, D. (2) 177–183
 Jiang, L.-X., see Xu, Y.-J. (1) 113–117
 Jiang, S., see Yan, H. (2) 185–192
 Jin, H., see Yuan, Q. (1) 93–101
 Jin, Q., see Yang, Z. (3) 313–325
 Jin, X., see Dou, C. (4) 447–454
 Jing, F., see Gao, P. (1) 11–20
- Karimipoor, M., see Rismani, E. (2) 151–159
 Karp, J.E., see Ding, J. (4) 353–363
 Ke, J., see Cai, Z. (2) 161–168
 Khan, Md.A., see Cheng, J. (1) 85–92
 Kohli, A., see Thein, M.S. (4) 383–391
 Kong, W., see Yuan, Q. (1) 93–101
 Kong, Z., see Zhang, Y. (2) 145–150
- La Follette, S.K., see Hanna, G.J. (2) 129–136
 Lai, X., see Chen, X. (4) 419–424
 Lan, P., see Cai, Z. (2) 161–168
 Lee, H.-J., see Choi, B. (3) 231–239
 Lei, T., see Chen, X. (4) 419–424
 Li, B., see Yan, H. (2) 185–192
 Li, C.-F., J. Zheng and Y.-W. Xue, The value of contrast-enhanced computed tomography in predicting gastric cancer recurrence and metastasis (3) 327–333
 Li, D., see Zhang, S. (1) 27–34
 Li, H., see Xue, L. (2) 193–197
 Li, H.-Z., see Wang, D. (2) 177–183
 Li, J., see Zhang, S. (1) 27–34
 Li, L., Q. Gao, G. Xu, B. Shi, X. Ma, H. Liu, Q. Li, T. Tian, J. Tang and H. Niu, Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods (4) 403–409
 Li, L., see Shen, H. (4) 365–373
 Li, L., W. Wang, R. Zhang, J. Liu, J. Yu, X. Wu, Y. Xu, M. Ma and J. Huang, High expression of LAMP2 predicts poor prognosis in patients with esophageal squamous cell carcinoma (3) 305–311
 Li, Q., see Li, L. (4) 403–409
 Li, Q., see Zhao, Q. (4) 455–463
 Li, T., see Dou, C. (4) 447–454
 Li, X., see Cai, Z. (2) 161–168
 Li, X., see Chen, E. (2) 207–212
 Li, Y., see Zhang, Y. (2) 145–150
 Li, Z., see Ning, L. (1) 75–83
 Liang, T., see Yang, N. (3) 263–269
 Lin, H., see Zhang, J. (3) 257–262
 Liu, B., see Hou, S.-Z. (3) 249–256
 Liu, C., X. He, X. Wu, Z. Wang, W. Zuo and G. Hu, Clinicopathological and prognostic significance of GPx2 protein expression in nasopharyngeal carcinoma (3) 335–340
 Liu, H., see Li, L. (4) 403–409
 Liu, H., see Rong, B. (1) 35–43
 Liu, J., B. Xu, G. Xu, X. Zhang, X. Yang and J. Wang, Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor (3) 241–248
 Liu, J., see Li, L. (3) 305–311
 Liu, N.-B., see Sun, J. (1) 45–50
 Liu, W., see Zhang, Z.J. (2) 169–175
 Lorch, J.H., see Hanna, G.J. (2) 129–136
 Lu, L., see Shen, Y. (3) 271–278
 Lv, C., see Zhang, S. (1) 27–34
 Lv, J., see Huang, Q. (2) 137–144
- Ma, M., see Li, L. (3) 305–311
 Ma, X., see Li, L. (4) 403–409
 Mahjoubi, F., see Motalebzadeh, J. (1) 51–55
 Mahmoodzadeh, H., see Rismani, E. (2) 151–159
 Maimaiti, Y., L. Dong, A. Aili, Maimaitiaili, T. Huang and K. Abudureyimu, Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors (4) 411–418
 Maimaitiaili, see Maimaiti, Y. (4) 411–418
 Man, D., see Yang, Z. (3) 313–325
 Margalit, D.N., see Hanna, G.J. (2) 129–136
 Mehdipour, P., see Estiar, M.A. (3) 341–351
 Mehrzin, M., see Estiar, M.A. (3) 341–351
 Mei, L.-L., Y.-T. Qiu, B. Zhang and Z.-Z. Shi, MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers and therapeutic targets (1) 1–9
 Méndez, J.P., see Canto, P. (3) 297–303
 Meng, Y., see Wang, S. (2) 199–205
 Min, J., see Choi, B. (3) 231–239
 Mosaad, H., see Hussein, S. (3) 279–287
 Motalebzadeh, J., F. Mahjoubi, N. Nafissi, M. Hashemian, M. Taheri and Y. Hosseinpour, *FBLN-4* and *BCRP* genes as two prognostic markers are downregulated in breast cancer tissue (1) 51–55
 Movassagh, A., see Rismani, E. (2) 151–159
 Mu, D., see Zhang, S. (1) 27–34
- Na, R., see Xue, L. (2) 193–197
 Nada, O., see Al Ahmed, H.A. (1) 21–26

- Nafissi, N., see Motalebzadeh, J. (1) 51–55
 Nan, J., see Xue, L. (2) 193–197
 Nan, Y., see Rong, B. (1) 35–43
 Ning, L., Z. Li, D. Wei, H. Chen and C. Yang, LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma (1) 75–83
 Niu, H., see Li, L. (4) 403–409
 Niu, S., see Du, Z. (2) 221–230
 Obradovic, M., see Petrovic, N. (2) 119–128
 Pan, J., see Chen, X. (4) 419–424
 Petrovic, N., R. Davidovic, V. Bajic, M. Obradovic and R.E. Isenovic, MicroRNA in breast cancer: The association with *BRCA1/2* (2) 119–128
 Prasad, K., see Bellampalli, R. (4) 393–401
 Qian, C., see Xu, Y.-J. (1) 113–117
 Qian, Z., see Deng, J. (1) 57–64
 Qiang, D., see Wang, S. (2) 199–205
 Qiu, Y.-T., see Mei, L.-L. (1) 1–9
 Qu, Y.-J., see Yang, N. (3) 263–269
 Rabinowits, G., see Hanna, G.J. (2) 129–136
 Rai, P.S., see Bellampalli, R. (4) 393–401
 Raish, M., see Ahmad, A. (4) 375–381
 Ram, R., see Thein, M.S. (4) 383–391
 Rashed, H.E., see Hussein, S. (3) 279–287
 Rismani, E., M.S. Fazeli, H. Mahmoodzadeh, A. Movasagh, S. Azami, M. Karimipoor and L. Teimoori-Toolabi, Pattern of LRP6 gene expression in tumoral tissues of colorectal cancer (2) 151–159
 Rojano-Mejía, D., see Canto, P. (3) 297–303
 Rong, B., Y. Nan, H. Liu and W. Gao, Increased stathmin correlates with advanced stage and poor survival of non-small cell lung cancer (1) 35–43
 Satyamoorthy, K., see Bellampalli, R. (4) 393–401
 Schoenfeld, J.D., see Hanna, G.J. (2) 129–136
 Shahid, M., see Ahmad, A. (4) 375–381
 Sharma, A.R., see Bellampalli, R. (4) 393–401
 Sharma, K., see Bellampalli, R. (4) 393–401
 Shen, D., see Hong, T. (1) 103–111
 Shen, H., L. Li, D. Wang, S. Yang, X. Chen, S. Zhou, S. Zhong, J. Zhao and J. Tang, Higher expression of SALL4 predicts poor cancer prognosis: A meta-analysis (4) 365–373
 Shen, Y., X. Wang, J. Xu and L. Lu, SerpinE2, a poor biomarker of endometrial cancer, promotes the proliferation and mobility of EC cells (3) 271–278
 Sheng, H., see Zhang, S. (1) 27–34
 Sheng, X., see Zhao, Q. (4) 455–463
 Shi, B., see Li, L. (4) 403–409
 Shi, L., see Wang, S. (2) 199–205
 Shi, Z.-Z., see Mei, L.-L. (1) 1–9
 Son, Y.-G., see Choi, B. (3) 231–239
 Sridharan, V., see Hanna, G.J. (2) 129–136
 Su, W., see Zhong, J.-T. (2) 213–220
 Su, Y., A. Zhao, G. Cheng, J. Xu, E. Ji and W. Sun, The IGF-I/JAK2-STAT3/miR-21 signaling pathway may be associated with human renal cell carcinoma cell growth (3) 289–296
 Suh, Y.-S., see Choi, B. (3) 231–239
 Sun, B., see Zhang, S. (1) 27–34
 Sun, C., see Wang, S. (2) 199–205
 Sun, J., N.-B. Liu, H.-Q. Zhuang, L.-J. Zhao, Z.-Y. Yuan and P. Wang, Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human Lung cancer cell (1) 45–50
 Sun, L., see Dou, C. (4) 447–454
 Sun, M., see Yan, H. (2) 185–192
 Sun, T., see Yuan, Q. (1) 93–101
 Sun, W., see Su, Y. (3) 289–296
 Sun, Y., see Hou, S.-Z. (3) 249–256
 Taheri, M., see Motalebzadeh, J. (1) 51–55
 Tang, J., see Li, L. (4) 403–409
 Tang, J., see Shen, H. (4) 365–373
 Tang, Y., see Deng, J. (1) 57–64
 Tania, M., see Cheng, J. (1) 85–92
 Tao, M., see Zhao, Q. (4) 455–463
 Tapia, A., see Canto, P. (3) 297–303
 Teimoori-Toolabi, L., see Rismani, E. (2) 151–159
 Tejeda, M.E., see Canto, P. (3) 297–303
 Thein, M.S., A. Kohli, R. Ram, M.C. Ingaramo, A. Jain and N.S. Fedarko, Chitotriosidase, a marker of innate immunity, is elevated in patients with primary breast cancer (4) 383–391
 Tian, Q., see Chen, X. (4) 419–424
 Tian, T., see Li, L. (4) 403–409
 Tishler, R.B., see Hanna, G.J. (2) 129–136
 Vohra, M., see Bellampalli, R. (4) 393–401
 Wan, X., see Zhang, Y. (2) 145–150
 Wang, C., see Huang, Q. (2) 137–144
 Wang, D., H.-Z. Li and Z.-G. Ji, Effectiveness and safety of laparoscopic enucleation combined with selective arterial embolization for renal angiomyolipoma (2) 177–183
 Wang, D., see Shen, H. (4) 365–373
 Wang, F., see Yang, B. (1) 65–73

- Wang, G., see Huang, Q. (2) 137–144
 Wang, H., see Huang, Q. (2) 137–144
 Wang, H.-J., see Zhong, J.-T. (2) 213–220
 Wang, J., see Cai, Z. (2) 161–168
 Wang, J., see Liu, J. (3) 241–248
 Wang, L., see Cai, Z. (2) 161–168
 Wang, P., see Sun, J. (1) 45–50
 Wang, R., see Yan, H. (2) 185–192
 Wang, S., J. Xu, Y. Meng, D. Qiang, C. Sun, L. Shi and E. Zhao, In situ memory T cells and patterns of invasion predict outcome in patients with early-stage oral squamous cell carcinoma (2) 199–205
 Wang, S., see Gao, P. (1) 11–20
 Wang, S.-F., see Zhong, J.-T. (2) 213–220
 Wang, W., see Deng, J. (1) 57–64
 Wang, W., see Li, L. (3) 305–311
 Wang, X., see Shen, Y. (3) 271–278
 Wang, X.-D., see Hou, S.-Z. (3) 249–256
 Wang, X.-W., see Yang, N. (3) 263–269
 Wang, X.-Y., see Zhang, J. (3) 257–262
 Wang, Y., see Gao, P. (1) 11–20
 Wang, Y., see Xue, L. (2) 193–197
 Wang, Z., see Liu, C. (3) 335–340
 Wei, C., see Cheng, J. (1) 85–92
 Wei, D., see Ning, L. (1) 75–83
 Wu, C., see Chen, X. (4) 419–424
 Wu, H., see Zhang, Y. (2) 145–150
 Wu, J., see Cheng, J. (1) 85–92
 Wu, J., see Yang, Z. (3) 313–325
 Wu, W., see Zhang, M. (4) 437–445
 Wu, X., see Cai, Z. (2) 161–168
 Wu, X., see Cai, Z. (2) 161–168
 Wu, X., see Hong, T. (1) 103–111
 Wu, X., see Li, L. (3) 305–311
 Wu, X., see Liu, C. (3) 335–340
 Wu, Y.-B., see Hou, S.-Z. (3) 249–256
- Xiao, J., see Cai, Z. (2) 161–168
 Xiao, X., see Cheng, J. (1) 85–92
 Xie, H., see Yang, Z. (3) 313–325
 Xing, J., see Zhang, S. (1) 27–34
 Xu, B., see Liu, J. (3) 241–248
 Xu, C., see Zhao, Q. (4) 455–463
 Xu, G., see Li, L. (4) 403–409
 Xu, G., see Liu, J. (3) 241–248
 Xu, H., see Zhao, Q. (4) 455–463
 Xu, J., see Shen, Y. (3) 271–278
 Xu, J., see Su, Y. (3) 289–296
 Xu, J., see Wang, S. (2) 199–205
 Xu, P., see Deng, J. (1) 57–64
 Xu, Q., see Du, Z. (2) 221–230
 Xu, X., see Du, Z. (2) 221–230
- Xu, Y., see Li, L. (3) 305–311
 Xu, Y.-J., C. Qian, J. He, D.-Q. Cheng and L.-X. Jiang, Thyroid cancer with concurrent breast tubular cancer: A case report and literature review (1) 113–117
 Xue, L., J. Nan, L. Dong, C. Zhang, H. Li, R. Na, H. He and Y. Wang, Upregulated miR-483-5p expression as a prognostic biomarker for esophageal squamous cell carcinoma (2) 193–197
 Xue, Y.-W., see Li, C.-F. (3) 327–333
 Xue, Z., see Yang, Z. (3) 313–325
- Yan, H., B. Li, T. Fan, S. Jiang, R. Wang and M. Sun, Clinical significance of serum dynamics of HSP90a level in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy (2) 185–192
 Yan, J., see Zhang, S. (1) 27–34
 Yang, B., Q. Guo, F. Wang, K. Cai, X. Bao and J. Chu, An 80-gene set potentially predicts the relapse in laryngeal carcinoma optimized by support vector machine (1) 65–73
 Yang, C., see Ning, L. (1) 75–83
 Yang, D., D. Zhao and X. Chen, MiR-133b inhibits proliferation and invasion of gastric cancer cells by up-regulating *FBNI* expression (4) 425–436
 Yang, H.-K., see Choi, B. (3) 231–239
 Yang, J., see Huang, Q. (2) 137–144
 Yang, N., Y.-J. Qu, Y. Cheng, T. Liang, M.-N. Zhang, D. Zhang, L.-N. Dong, X.-W. Wang and G.-M. Zhang, Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway (3) 263–269
 Yang, S., see Shen, H. (4) 365–373
 Yang, X., see Liu, J. (3) 241–248
 Yang, X., see Zhong, J.-T. (2) 213–220
 Yang, Z., Q. Jin, W. Hu, L. Dai, Z. Xue, D. Man, L. Zhou, H. Xie, J. Wu and S. Zheng, 14-3-3 σ down-regulation suppresses ICC metastasis via impairing migration, invasion, and anoikis resistance of ICC cells (3) 313–325
 Yao, Z., see Zhang, S. (1) 27–34
 Ye, F., see Yuan, Q. (1) 93–101
 Ye, Y., see Chen, E. (2) 207–212
 Yu, J., see Li, L. (3) 305–311
 Yu, J., see Zhong, J.-T. (2) 213–220
 Yuan, M.-X., see Hou, S.-Z. (3) 249–256
 Yuan, Q., T. Sun, F. Ye, W. Kong and H. Jin, MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting *AURKA* (1) 93–101

- Yuan, X., see Chen, E. (2) 207–212
Yuan, Z.-Y., see Sun, J. (1) 45–50
- Zekri, A., see Estiar, M.A. (3) 341–351
Zhan, J., see Gao, P. (1) 11–20
Zhang, B., see Dou, C. (4) 447–454
Zhang, B., see Mei, L.-L. (1) 1–9
Zhang, C., see Xue, L. (2) 193–197
Zhang, D., see Yang, N. (3) 263–269
Zhang, D.-Q., see Zhang, J. (3) 257–262
Zhang, G., see Deng, J. (1) 57–64
Zhang, G.-M., see Yang, N. (3) 263–269
Zhang, H., see Huang, Q. (2) 137–144
Zhang, J., H. Lin, X.-Y. Wang, D.-Q. Zhang, J.-X. Chen, Y. Zhuang and X.-L. Zheng, Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma (3) 257–262
Zhang, J.-H., see Zhong, J.-T. (2) 213–220
Zhang, M., W. Wu, M. Gao and Z. Fei, MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma (4) 437–445
Zhang, M.-N., see Yang, N. (3) 263–269
Zhang, R., see Li, L. (3) 305–311
Zhang, S., J. Li, G. Zhou, D. Mu, J. Yan, J. Xing, Z. Yao, H. Sheng, D. Li, C. Lv, B. Sun, Q. Hong and H. Guo, Aurora-A regulates autophagy through the Akt pathway in human prostate cancer (1) 27–34
Zhang, X., see Liu, J. (3) 241–248
Zhang, Y., see Zhang, Y. (2) 145–150
Zhang, Y., Z. Kong, Y. Zhang, W. Huang, H. Wu, X. Wan and Y. Li, Increased expression of long non-coding RNA GLDR in prostate cancer (2) 145–150
Zhang, Z., see Huang, Q. (2) 137–144
Zhang, Z.J., Y. Cao, W. Zhao, L. Guo and W. Liu, HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma (2) 169–175
Zhao, A., see Su, Y. (3) 289–296
Zhao, D., see Yang, D. (4) 425–436
Zhao, E., see Wang, S. (2) 199–205
Zhao, J., see Shen, H. (4) 365–373
Zhao, L.-J., see Sun, J. (1) 45–50
Zhao, Q., Z. Cui, Y. Zheng, Q. Li, C. Xu, X. Sheng, M. Tao and H. Xu, Fenofibrate protects against acute myocardial I/R injury in rat by suppressing mitochondrial apoptosis as decreasing cleaved caspase-9 activation (4) 455–463
Zhao, W., see Zhang, Z.J. (2) 169–175
Zheng, F., see Chen, E. (2) 207–212
Zheng, J., see Li, C.-F. (3) 327–333
Zheng, S., see Yang, Z. (3) 313–325
Zheng, X.-L., see Zhang, J. (3) 257–262
Zheng, Y., see Zhao, Q. (4) 455–463
Zhong, J.-T., H.-J. Wang, J. Yu, J.-H. Zhang, S.-F. Wang, X. Yang and W. Su, Correlations of the expressions of c-Jun and Egr-1 proteins with clinicopathological features and prognosis of patients with nasopharyngeal carcinoma (2) 213–220
Zhong, S., see Shen, H. (4) 365–373
Zhou, B., see Cheng, J. (1) 85–92
Zhou, G., see Zhang, S. (1) 27–34
Zhou, L., see Yang, Z. (3) 313–325
Zhou, S., see Shen, H. (4) 365–373
Zhou, Y., see Deng, J. (1) 57–64
Zhuang, H.-Q., see Sun, J. (1) 45–50
Zhuang, Y., see Zhang, J. (3) 257–262
Zou, Y., see Cai, Z. (2) 161–168
Zuo, W., see Liu, C. (3) 335–340